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Purpose: The aim of this study was to evaluate the antimicrobial activity of Thonningia 
sanguinea against two sensitive and two multi-drug resistant (ESBL) Enterobacteria strains 
namely Escherichia coli and Klebsiella pneumoniae. 
Method: The confirmation of the ESBL producing strains was done by the double-disc 
synergy tests and the broth dilution method was used for the determination of the 
antimicrobial parameters (MIC and MBC) on these sensitive and ESBL producing strains. 
Results: The two sensitive strains had the same MIC and MBC values respectively 3.125 mg 
/ml and 12.50 mg/ml. The ESBL producing strains also had the same MIC of 6.25 mg /ml and 
MBC values of 25 mg/ml. The extract was bactericidal for all tested strains. 
Conclusion: The results suggest that the flowers of T. sanguinea can be used in association 
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INTRODUCTION 
Medicinal plants have long been utilized as a 
source of therapeutic agents worldwide. 
Recently, herbal medicines have increasingly 
been used to treat many difficult diseases 
including several infections. In Ivory Coast, 
Alternanthera repens (Zakrékokréko) and 
Kalankoe crenata (Kpakolo), respectively, are 
used for the treatment of paludism and asthma1. 
Plants are known to produce certain chemicals 
which are naturally toxic to bacteria 2. In fact, the 
extract of each plant contains different 
secondary metabolites 3.  
Infectious diseases are the world’s leading 
cause of premature deaths, killing almost 50,000 
people every day4. In recent years, drug 
resistance to human pathogenic bacteria has 
been commonly reported from all over the world 
5. Among the wide array of antibiotics, β-lactams 
are the most varied and widely used agents 
accounting for over 50% of all systemic 
antibiotics in use 6. The most common cause of 
bacterial resistance to β-lactam antibiotics is the 
production of β-lactamases. Bacterial resistance 
to β-lactam antibiotics has significantly increased 
in recent years. This increase has been 
attributed to the spread of plasmid-mediated 
extended spectrum β-lactamases (ESBLs) 7. 
ESBLs occur predominantly in the family of 
Enterobacteriaceae. Klebsiella pneumoniae and 
E.coli are the main species in which ESBL 
enzymes have been most commonly reported 
worldwide, and it is responsible for 5% – 20% of 
outbreaks of nosocomial infections in intensive 
care units, as well as burn, oncology and 
neonatal units 8. ESBL-producing strains are 
usually resistant to all aminoglycosides, third- 
and fourth-generation cephalosporins and 
monobactams 9. 
For the time being, these strains remain 
generally susceptible to cephamycins, 
carbapenems and β-lactamase inhibitor-β-lactam 
combinations 9. 
The present scenario of emergence of multiple 
drug resistance of human pathogenic organisms 
has necessitated a search for new antimicrobial 
substances from other sources including plants 
10. In previous studies, the extract of the flowers 
of Thonningia sanguinea showed promising 
antibacterial activity against a MDR strain of 
Salmonella Enteritidis Lysotype 6, a member of 
Enterobacteriaceae family 11.   
In the present study, we have choosen this 
ivorian medicinal plant T. sanguinea to screen its 
antimicrobial activity (MIC and MBC) against 
others multi-drug resistant (ESBL) 
Enterobacteria namely Escherichia coli and 
Klebsiella pneumonia and two sensitive strains 
of these bacteria. 
 
MATERIAL AND METHODS 
Plant material 
T. sanguinea flowers were collected in Adzopé, 
Côte d’Ivoire (West Africa) and identified by Pr 
Aké-Assi of the Department of Botany, University 
of Cocody-Abidjan. A voucher specimen 
(Voucher no. 14162) is deposited in the 
herbarium of Centre National de Floristique 
(CNF) of Abidjan.  
Bacterial strains 
The biological assays were carried out on 4 
hospital isolates provided by the Laboratoire de 
Bactériologie & Virologie of Institut Pasteur de 
Côte d’Ivoire. The strains were house 
refecenced. According to the activity of known 
antibiotics, two kinds of strain were 
distinguished: some strains were sensitive (E. 
coli no. 513/06; Klebsiella pneumoniae no.  
515/06) and others were resistant (E coli ESBL 
no. 1963; Klebsiella pneumoniae ESBL no. 
1911).  
Extraction procedure 
The freshly collected flowers of the plant were air 
dried at room temperature for 7 days and 
powdered. Briefly 20g of powder was soaked in 
500ml distilled water for 24 h with constant 
stirring. The suspension was further filtered 
through Whatman (No. 1) filter paper. The filtrate 
was concentrated in vacuo using a rotary 
evaporator to obtain the aqueous extract.  
Antibacterial tests 
Confirmatory test for ESBL-producing K. 
pneumoniae and E.coli isolates 
The double-disc synergy tests were used as 
screening tools to detect ESBL-producing 
strains. In the double-disc synergy test, 
cefotaxime (30µg), ceftazidime (30µg), cefepime 
(30 µg) and Aztreonam (30µg) discs were placed 
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on Mueller-Hinton agar adjacent to a co-
amoxiclav disc (20µg amoxycillin plus 10µg 
clavulanate). All discs were purchased from 
Biorad (France). The procedures and 
interpretation of the double-disc synergy test 
were described previously12. 
Determination of Minimum Inhibtory 
Concentration (MIC) 
The Minimal Inhibitory Concentration (MIC) was 
determined according to Wilkinson and Gentry 
13. Two-fold dilutions (six) of the extract were 
carried out starting from the concentration of 5 
mg/ml. The tubes were inoculated with a 
microorganism suspension at a final density of 
105 cells/ml. The tubes were incubated at 37 °C 
for 24 h. The lowest concentration of the tube 
which did not show any visible growth after 
macroscopic evaluation was considered as the 
MIC.  
Determination of MBC 
The Minimal Bactericidal Concentration (MBC) is 
defined as the concentration producing a 99.9% 
reduction in colony forming units (CFU) number 
in the initial inoculum. It was determined by 
subculture on nutrient agar as previously 
described 14. 
The tubes without growth after 24 h of incubation 
were subcultured on Mueller Hinton agar in Petri 
dishes for 24 h. MBC was determined as the 
lowest concentration that showed no bacterial 




Phenotypic confirmation of ESBLs was carried 
out by the double-disc synergy tests (Figure 1). 
Of the four clinical isolates of K. pneumoniae 
and E. coli, two were confirmed to be ESBL 
producing isolates by the double disc synergy 
test according to Wu et al. 12. Double-disc tests 
showed synergy for co-amoxiclav with 
cefotaxime, aztreonam and cefepime against 
both  E. coli (no. 1963) and K. pneumoniae (no. 
1911) strains. The tests were performed in 
triplicate.   
Antimicrobial activity of the extract 
The sensitive strains tested showed some 
degree of sensitivity to the aqueous extract. The  
MIC results of the extract on the different strains 
are shown in Table 1. 
The two sensitive strains had the same MIC and 
MBC values (3.125 mg /ml and 12.50 mg/ml, 
respectively). The calculation of MBC/MIC ratio 
shows that this value is equal to 4 for 
K.pneumoniae and E.coli (Table1). The aqueous 
extract of the flowers of Thonningia sanguinea is 
bactericidal for these tested strains. 
The ESBL producing strains tested also showed 
various degrees of sensitivity to the aqueous 
extract. The resistant strains had the same MIC 
value of 6.25 mg /ml) and MBC value of 25 
mg/ml.  
The calculation of MBC/MIC shows that this 
value is equal to 4 for all the ESBL producing 
strains (Table 1). The aqueous extract of the 
flowers of Thonningia sanguinea is bactericidal 
for these tested strains. The extract was 
bactericidal at the MBC concentrations for all the 
tested strains.  
Table 1: Antibacterial acitivity of Thonningia sanguinea  
 
 
           Antibacterial parameters (mg/ml)  
Sensitive strains MIC  MBC  MIC/MBC 
E .coli N°513/06 3.125 12.50 4 
K. pneumoniaeN° 515/06 3.125 12.50 4 
ESBL strains    
E. coli N° 1963 6.250 25 4 
K .pneumoniae  N° 1911 6.250 25 4 
N’guessennd et al                     
 
Trop J Pharm Res September 2007; 6 (3) 782
 DISCUSSION 
The pathogenic role of E. coli, K. pneumoniae 
infection in the development of human diseases 
and the impact of resistance on the clinical 
outcome stimulated the search for newer 
treatments and the use of natural agents as 
alternative therapies. The therapeutic challenges 
resulting from emerging antimicrobial 
resistances have compromised chemotherapy 
for hospitalized patients with severe infections. 
ESBL is one of the prevalent resistance 
problems. Most of the clinical isolates producing 
ESBL have originated from hospitalized patients 
and have frequently caused nosocomial 
outbreaks16.  
In the present investigation, we have evaluated 
the antimicrobial activity of the aqueous extract 
of T. sanguinea against sensitive and ESBL 
strains of E. coli and K. pneumoniae.  
Our results clearly indicated the inhibitory effects 
of the extract of T. sanguinea on these bacteria. 
Ohiri and Uzodinma 17 had  already shown the 
inhibitory activity of T. sanguinea on sensitive 
strains of E. coli, K. pneumoniae. 
In our study, an interesting finding is the 
inhibition of the ESBL strains by the aqueous 
extract of T. sanguinea. The results showed 
significant inhibition with promising antibacterial 
parameters (MIC values between 3.125 and 
6.250 mg/ml). The minimum bactericidal 
concentration (MBC) was always found to be 4-
fold higher than MIC values. The results 
revealed that the extract exhibited bactericidal 
activity against the tested strains. T. sanguinea 
is traditionally used in Côte d’Ivoire for the 
treatment of diarrhoeal diseases Thus, these 
results support its use in traditional medicine. 
Previous phytochemical screening of the 
aqueous extract of the flowers of T. sanguinea 
has shown the presence of saponins, quinons, 
flavonoids18. 
The flavonoids in the extract may account for the 
antimicrobial activity against K. pneumoniae. 
This group of secondary metabolites have also 
been detected in T. sanguinea by Ohiri and 
Uzodinma 17. Flavonoids are common secondary 
metabolites in plants. They were described in 
previous papers as exhibiting antibacterial 
activities against gram-positive [e.g. methicillin-
resistant Staphylococcus aureus (MRSA)] and 
K.pneumoniae bacteria 10; 19 as well as inhibiting 
the growth of lactic acid bacteria of human 
gastrointestinal tract origin 20. Lin et al. 10 
proposed the combination of antibiotics and 
flavonoids as a potential new strategy for the 
development of new therapies for infections 
 
          ESBL producing E. coli         ESBL producing K. Pneumoniae 
 
Figure 1: Confirmatory tests of ESBL strains (1 = Ceftazidime; 2 = Ceftriaxone; 3 = Cefoxitin; 4 = 
Cefotaxime; 5 = Amoxicilin+Clavulanic acid; 6 = Aztreonam; 7 = Cefalotin; 8 = Meticilinam; 9 = Cefepime; 10 
= Imipenem; 11. Piperaciline; 12 = Ticarcilin; 13 = Amoxicilin; 14 = Ampicilin) 
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caused by ESBL-producing bacteria in the 
future. 
Conclusion 
From the foregoing, our results suggest that the 
flowers of T. sanguinea can be used in 
association with antibiotics for alternative 
therapy of diseases caused by ESBL producing  
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